Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,322.00
Bid: 12,320.00
Ask: 12,324.00
Change: 204.00 (1.68%)
Spread: 4.00 (0.032%)
Open: 12,244.00
High: 12,384.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Stocks hold onto gains amid US rate cut hopes

Wed, 27th Dec 2023 12:06

(Alliance News) - London's FTSE 100 index was outperforming other European stock-price measures at midday on Wednesday, boosted by gains for miners and industrials.

The FTSE 100 index was up 43.08 points, 0.6%, at 7,740.59. The FTSE 250 was up 55.22 points, 0.3%, at 19,686.17, and the AIM All-Share was up 7.04 points, 0.9%, at 761.44.

The Cboe UK 100 was up 0.5% at 772.79, the Cboe UK 250 was up 0.4% at 17,174.23, and the Cboe Small Companies was up 0.1% at 14,746.53.

The CAC 40 in Paris and the DAX 40 in Frankfurt were both up 0.2%.

Market sentiment was still cheery in Europe, as investors responded to a cooler-than-expected US inflation reading before Christmas.

After the early close in London on Friday, data from the US showed inflation eased a bit more in November.

The Bureau of Economic Analysis said the core personal consumption expenditures price index rose annually by 3.2% in November, slowing from 3.4% in October, which was first reported at 3.5%. The latest figure was just below the FXStreet-cited market consensus of 3.3%.

The core reading, the Fed's preferred inflation gauge, does not include food or energy.

According to CME's FedWatch tool, a majority of market participants are pricing in five consecutive 25-basis-point rate cuts beginning from the March policy meeting. This would bring the target range on federal funds to a 400 to 425 basis point range - meaning 4.00% to 4.25% - come September, from the current 525 to 550. Another 25 basis point cut is expected before the close of 2024.

"It's safe to say that the mood heading into the new year is significantly more favourable than a year ago. Inflation is moderating; a soft landing is now the consensus view, and approximately 150 basis points of easing are priced in for 2024. So what possibly could go wrong?" mused SPI Asset Management's Stephen Innes.

"I guess the question is, what will be the next significant catalyst for stocks to move higher, especially with so much rate-cut euphoria baked into the holiday cake?" he considered.

Stocks in New York were called to open fairly flat on Wednesday. The Dow Jones Industrial Average and the S&P 500 index were called marginally lower, but the Nasdaq Composite was pointed slightly into the green.

The dollar lost ground against the pound and the euro over the long holiday weekend in Europe but made gains against the yen.

Sterling was quoted at USD1.2730 at midday in London on Wednesday, higher than USD1.2719 at the London equities close on Friday. The euro traded at USD1.1054, up from USD1.1019. Against the yen, the dollar was quoted at JPY142.60, up versus JPY142.14.

Gold was quoted at USD2,065.93 an ounce at midday on Wednesday in London, higher than USD2,055.55 shortly after midday in London on Friday. Brent oil was trading at USD80.65 a barrel, up from USD80.02.

In London, Aviva edged into the green, up 0.1%.

The insurer said it will receive an extra GBP80.0 million of additional proceeds for its 26% stake in Singaporean insurance provider Singapore Life. This would bring the total amount Aviva will receive to around GBP930 million from Osaka, Japan-based buyer Sumitomo Life Insurance.

AstraZeneca added 1.6%.

Astra announced on Tuesday it has agreed to buy Nasdaq-listed Gracell Biotechnologies and will pay about USD1.2 billion for the clinical-stage company. The Cambridge, England-based pharmaceutical company said it expects the acquisition to close in the first quarter of 2024.

Gracell is a Suzhou, China-based biopharmaceutical firm developing cell therapies for cancer and autoimmune diseases. AstraZeneca will pay USD2.00 per share, or USD10.00 per American depositary share, for Gracell at closing, plus USD0.30 per share "upon achievement of a specified regulatory milestone".

The upfront cash portion represents a transaction value of around USD1.0 billion, with the total value being about USD1.2 billion if the milestone is achieved. Gracell ADSs closed up 60% at USD9.92 in New York on Tuesday.

Also in London, large-cap miners and industrial firms held on to their morning gains, with Anglo American up 3.5%, Ashtead up 1.8%, and Glencore up 1.7%.

Retailers such as Next and Marks & Spencer saw some weakness, down 0.6% and 0.4% around midday.

According to MRI Software, footfall at the UK's retail destinations was more than a fifth lower this Boxing Day than a year ago. MRI said footfall had been 2.3% higher than last year by 3pm, but across the full day shoppers dropped off significantly compared to 2022.

"Black Friday promotions have also stolen a march on the traditional in-store Boxing Day sales, with many more people hoping to grab a discount from the comfort of the sofa," commented Hargreaves Lansdown's Susannah Streeter.

On AIM, shares in Horizonte Minerals surged 25%.

The London-based nickel development company celebrated securing a USD20 million funding package "that will allow for critical construction streams to advance at its flagship Araguaia nickel project" in Brazil, and serve as working capital.

Still to come on Wednesday's economic calendar, there's the Johnson Redbook retail sales index in the US.

By Elizabeth Winter, Alliance News deputy news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
Today 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
Today 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.